Cargando…

SGLT2 Inhibitors—A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling

Detalles Bibliográficos
Autores principales:	Yagi, Takashi, Kolluru, Gopi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375488/ https://www.ncbi.nlm.nih.gov/pubmed/35906180 http://dx.doi.org/10.1161/JAHA.122.026774

Ejemplares similares

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023)

Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing
por: Kolluru, Gopi Krishna, et al.
Publicado: (2012)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Shiba, Kumiko, et al.
Publicado: (2018)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
por: Jojima, Teruo, et al.
Publicado: (2019)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin, an Inhibitor of the Na(+)-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
por: Shim, Bosung, et al.
Publicado: (2023)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
por: Rahadian, Arief, et al.
Publicado: (2020)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
por: Nishinarita, Ryo, et al.
Publicado: (2021)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Hydrogen Sulfide Stimulates Ischemic Vascular Remodeling Through Nitric Oxide Synthase and Nitrite Reduction Activity Regulating Hypoxia‐Inducible Factor‐1α and Vascular Endothelial Growth Factor–Dependent Angiogenesis
por: Bir, Shyamal C., et al.
Publicado: (2012)

Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
por: Leopold, Jane A., et al.
Publicado: (2016)

The Molecular Mechanism of Aerobic Exercise Improving Vascular Remodeling in Hypertension
por: Song, Yinping, et al.
Publicado: (2022)

The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway
por: Yang, Xuping, et al.
Publicado: (2020)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018)

Pathophysiology of Vascular Remodeling in Hypertension
por: Renna, Nicolás F., et al.
Publicado: (2013)

Vascular Remodeling in Experimental Hypertension
por: Risler, Norma R., et al.
Publicado: (2005)

Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
por: Bader, Nimrah, et al.
Publicado: (2016)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

Redox signaling, Nox5 and vascular remodeling in hypertension
por: Montezano, Augusto C., et al.
Publicado: (2015)

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
por: Kuo, Hsiao-Huai, et al.
Publicado: (2023)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Cellular and Molecular Defects Underlying Invasive Fungal Infections—Revelations from Endemic Mycoses
por: Lee, Pamela P., et al.
Publicado: (2017)

Pulmonary Vascular Remodeling in Pulmonary Hypertension
por: Jia, Zhuangzhuang, et al.
Publicado: (2023)

Tuberculosis associated pulmonary hypertension: The revelation of a clinical observation
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2016)

Oxidative Stress, Vascular Remodeling, and Vascular Inflammation in Hypertension
por: Renna, Nicolas Federico
Publicado: (2013)

Revelation at Gargamelle
Publicado: (1978)

Révélations atomiques
por: Cardan, J
Publicado: (1954)

Cannot write session to /tmp/vufind_sessions/sess_f3394ie8d7e7255kmc1rkmhksr